Compile Data Set for Download or QSAR
Report error Found 155 Enz. Inhib. hit(s) with all data for entry = 11861
TargetProtein cereblon(Human)
Monte Rosa Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 653968BDBM653968(US11912682, Compound 66)
Affinity DataIC50: 500nMAssay Description:Compound activity was monitored in a fluorescence polarization (FP) homogeneous assay using 1-[5-({2-[2-(2-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2024
Entry Details
US Patent

TargetProtein cereblon(Human)
Monte Rosa Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 653971BDBM653971(US11912682, Compound 69)
Affinity DataIC50: 500nMAssay Description:Compound activity was monitored in a fluorescence polarization (FP) homogeneous assay using 1-[5-({2-[2-(2-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2024
Entry Details
US Patent

TargetProtein cereblon(Human)
Monte Rosa Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 653965BDBM653965(US11912682, Compound 63)
Affinity DataIC50: 500nMAssay Description:Compound activity was monitored in a fluorescence polarization (FP) homogeneous assay using 1-[5-({2-[2-(2-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2024
Entry Details
US Patent

TargetProtein cereblon(Human)
Monte Rosa Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 653967BDBM653967(US11912682, Compound 65)
Affinity DataIC50: 500nMAssay Description:Compound activity was monitored in a fluorescence polarization (FP) homogeneous assay using 1-[5-({2-[2-(2-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2024
Entry Details
US Patent

TargetProtein cereblon(Human)
Monte Rosa Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 654030BDBM654030(US11912682, Compound 129)
Affinity DataIC50: 500nMAssay Description:Compound activity was monitored in a fluorescence polarization (FP) homogeneous assay using 1-[5-({2-[2-(2-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2024
Entry Details
US Patent

TargetProtein cereblon(Human)
Monte Rosa Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 653977BDBM653977(US11912682, Compound 75)
Affinity DataIC50: 500nMAssay Description:Compound activity was monitored in a fluorescence polarization (FP) homogeneous assay using 1-[5-({2-[2-(2-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2024
Entry Details
US Patent

TargetProtein cereblon(Human)
Monte Rosa Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 653976BDBM653976(US11912682, Compound 74)
Affinity DataIC50: 500nMAssay Description:Compound activity was monitored in a fluorescence polarization (FP) homogeneous assay using 1-[5-({2-[2-(2-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2024
Entry Details
US Patent

TargetProtein cereblon(Human)
Monte Rosa Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 653972BDBM653972(US11912682, Compound 70)
Affinity DataIC50: 500nMAssay Description:Compound activity was monitored in a fluorescence polarization (FP) homogeneous assay using 1-[5-({2-[2-(2-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2024
Entry Details
US Patent

TargetProtein cereblon(Human)
Monte Rosa Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 654036BDBM654036(US11912682, Compound 135)
Affinity DataIC50: 500nMAssay Description:Compound activity was monitored in a fluorescence polarization (FP) homogeneous assay using 1-[5-({2-[2-(2-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2024
Entry Details
US Patent

TargetProtein cereblon(Human)
Monte Rosa Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 653975BDBM653975(US11912682, Compound 73)
Affinity DataIC50: 500nMAssay Description:Compound activity was monitored in a fluorescence polarization (FP) homogeneous assay using 1-[5-({2-[2-(2-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2024
Entry Details
US Patent

TargetProtein cereblon(Human)
Monte Rosa Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 654016BDBM654016(US11912682, Compound 115)
Affinity DataIC50: 500nMAssay Description:Compound activity was monitored in a fluorescence polarization (FP) homogeneous assay using 1-[5-({2-[2-(2-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2024
Entry Details
US Patent

TargetProtein cereblon(Human)
Monte Rosa Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 654013BDBM654013(US11912682, Compound 112)
Affinity DataIC50: 500nMAssay Description:Compound activity was monitored in a fluorescence polarization (FP) homogeneous assay using 1-[5-({2-[2-(2-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2024
Entry Details
US Patent

TargetProtein cereblon(Human)
Monte Rosa Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 653948BDBM653948(US11912682, Compound 46)
Affinity DataIC50: 500nMAssay Description:Compound activity was monitored in a fluorescence polarization (FP) homogeneous assay using 1-[5-({2-[2-(2-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2024
Entry Details
US Patent

TargetProtein cereblon(Human)
Monte Rosa Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 654012BDBM654012(US11912682, Compound 111)
Affinity DataIC50: 500nMAssay Description:Compound activity was monitored in a fluorescence polarization (FP) homogeneous assay using 1-[5-({2-[2-(2-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2024
Entry Details
US Patent

TargetProtein cereblon(Human)
Monte Rosa Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 654015BDBM654015(US11912682, Compound 114)
Affinity DataIC50: 500nMAssay Description:Compound activity was monitored in a fluorescence polarization (FP) homogeneous assay using 1-[5-({2-[2-(2-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2024
Entry Details
US Patent

TargetProtein cereblon(Human)
Monte Rosa Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 654014BDBM654014(US11912682, Compound 113)
Affinity DataIC50: 500nMAssay Description:Compound activity was monitored in a fluorescence polarization (FP) homogeneous assay using 1-[5-({2-[2-(2-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2024
Entry Details
US Patent

TargetProtein cereblon(Human)
Monte Rosa Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 653961BDBM653961(US11912682, Compound 59)
Affinity DataIC50: 500nMAssay Description:Compound activity was monitored in a fluorescence polarization (FP) homogeneous assay using 1-[5-({2-[2-(2-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2024
Entry Details
US Patent

TargetProtein cereblon(Human)
Monte Rosa Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 654025BDBM654025(US11912682, Compound 124)
Affinity DataIC50: 500nMAssay Description:Compound activity was monitored in a fluorescence polarization (FP) homogeneous assay using 1-[5-({2-[2-(2-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2024
Entry Details
US Patent

TargetProtein cereblon(Human)
Monte Rosa Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 654027BDBM654027(US11912682, Compound 126)
Affinity DataIC50: 500nMAssay Description:Compound activity was monitored in a fluorescence polarization (FP) homogeneous assay using 1-[5-({2-[2-(2-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2024
Entry Details
US Patent

TargetProtein cereblon(Human)
Monte Rosa Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 653962BDBM653962(US11912682, Compound 60)
Affinity DataIC50: 500nMAssay Description:Compound activity was monitored in a fluorescence polarization (FP) homogeneous assay using 1-[5-({2-[2-(2-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2024
Entry Details
US Patent

TargetProtein cereblon(Human)
Monte Rosa Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 653956BDBM653956(US11912682, Compound 54)
Affinity DataIC50: 500nMAssay Description:Compound activity was monitored in a fluorescence polarization (FP) homogeneous assay using 1-[5-({2-[2-(2-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2024
Entry Details
US Patent

TargetProtein cereblon(Human)
Monte Rosa Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 654023BDBM654023(US11912682, Compound 122)
Affinity DataIC50: 500nMAssay Description:Compound activity was monitored in a fluorescence polarization (FP) homogeneous assay using 1-[5-({2-[2-(2-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2024
Entry Details
US Patent

TargetProtein cereblon(Human)
Monte Rosa Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 653937BDBM653937(US11912682, Compound 35)
Affinity DataIC50: 500nMAssay Description:Compound activity was monitored in a fluorescence polarization (FP) homogeneous assay using 1-[5-({2-[2-(2-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2024
Entry Details
US Patent

TargetProtein cereblon(Human)
Monte Rosa Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 653938BDBM653938(US11912682, Compound 36)
Affinity DataIC50: 500nMAssay Description:Compound activity was monitored in a fluorescence polarization (FP) homogeneous assay using 1-[5-({2-[2-(2-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2024
Entry Details
US Patent

TargetProtein cereblon(Human)
Monte Rosa Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 653996BDBM653996(US11912682, Compound 94)
Affinity DataIC50: 500nMAssay Description:Compound activity was monitored in a fluorescence polarization (FP) homogeneous assay using 1-[5-({2-[2-(2-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2024
Entry Details
US Patent

TargetProtein cereblon(Human)
Monte Rosa Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 653932BDBM653932(US11912682, Compound 30)
Affinity DataIC50: 500nMAssay Description:Compound activity was monitored in a fluorescence polarization (FP) homogeneous assay using 1-[5-({2-[2-(2-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2024
Entry Details
US Patent

TargetProtein cereblon(Human)
Monte Rosa Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 654009BDBM654009(US11912682, Compound 107)
Affinity DataIC50: 500nMAssay Description:Compound activity was monitored in a fluorescence polarization (FP) homogeneous assay using 1-[5-({2-[2-(2-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2024
Entry Details
US Patent

TargetProtein cereblon(Human)
Monte Rosa Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 654011BDBM654011(US11912682, Compound 110)
Affinity DataIC50: 500nMAssay Description:Compound activity was monitored in a fluorescence polarization (FP) homogeneous assay using 1-[5-({2-[2-(2-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2024
Entry Details
US Patent

TargetProtein cereblon(Human)
Monte Rosa Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 654010BDBM654010(US11912682, Compound 108)
Affinity DataIC50: 500nMAssay Description:Compound activity was monitored in a fluorescence polarization (FP) homogeneous assay using 1-[5-({2-[2-(2-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2024
Entry Details
US Patent

TargetProtein cereblon(Human)
Monte Rosa Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 653942BDBM653942(US11912682, Compound 40)
Affinity DataIC50: 500nMAssay Description:Compound activity was monitored in a fluorescence polarization (FP) homogeneous assay using 1-[5-({2-[2-(2-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2024
Entry Details
US Patent

TargetProtein cereblon(Human)
Monte Rosa Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 654049BDBM654049(US11912682, Compound 149)
Affinity DataIC50: 500nMAssay Description:Compound activity was monitored in a fluorescence polarization (FP) homogeneous assay using 1-[5-({2-[2-(2-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2024
Entry Details
US Patent

TargetProtein cereblon(Human)
Monte Rosa Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 653984BDBM653984(US11912682, Compound 82)
Affinity DataIC50: 500nMAssay Description:Compound activity was monitored in a fluorescence polarization (FP) homogeneous assay using 1-[5-({2-[2-(2-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2024
Entry Details
US Patent

TargetProtein cereblon(Human)
Monte Rosa Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 654051BDBM654051(US11912682, Compound 151)
Affinity DataIC50: 500nMAssay Description:Compound activity was monitored in a fluorescence polarization (FP) homogeneous assay using 1-[5-({2-[2-(2-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2024
Entry Details
US Patent

TargetProtein cereblon(Human)
Monte Rosa Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 653986BDBM653986(US11912682, Compound 84)
Affinity DataIC50: 500nMAssay Description:Compound activity was monitored in a fluorescence polarization (FP) homogeneous assay using 1-[5-({2-[2-(2-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2024
Entry Details
US Patent

TargetProtein cereblon(Human)
Monte Rosa Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 653980BDBM653980(US11912682, Compound 78)
Affinity DataIC50: 500nMAssay Description:Compound activity was monitored in a fluorescence polarization (FP) homogeneous assay using 1-[5-({2-[2-(2-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2024
Entry Details
US Patent

TargetProtein cereblon(Human)
Monte Rosa Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 653983BDBM653983(US11912682, Compound 81)
Affinity DataIC50: 500nMAssay Description:Compound activity was monitored in a fluorescence polarization (FP) homogeneous assay using 1-[5-({2-[2-(2-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2024
Entry Details
US Patent

TargetProtein cereblon(Human)
Monte Rosa Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 653982BDBM653982(US11912682, Compound 80)
Affinity DataIC50: 500nMAssay Description:Compound activity was monitored in a fluorescence polarization (FP) homogeneous assay using 1-[5-({2-[2-(2-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2024
Entry Details
US Patent

TargetProtein cereblon(Human)
Monte Rosa Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 653918BDBM653918(US11912682, Compound 16)
Affinity DataIC50: 500nMAssay Description:Compound activity was monitored in a fluorescence polarization (FP) homogeneous assay using 1-[5-({2-[2-(2-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2024
Entry Details
US Patent

TargetProtein cereblon(Human)
Monte Rosa Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 654057BDBM654057(US11912682, Compound 157)
Affinity DataIC50: 500nMAssay Description:Compound activity was monitored in a fluorescence polarization (FP) homogeneous assay using 1-[5-({2-[2-(2-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2024
Entry Details
US Patent

TargetProtein cereblon(Human)
Monte Rosa Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 654056BDBM654056(US11912682, Compound 156)
Affinity DataIC50: 500nMAssay Description:Compound activity was monitored in a fluorescence polarization (FP) homogeneous assay using 1-[5-({2-[2-(2-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2024
Entry Details
US Patent

TargetProtein cereblon(Human)
Monte Rosa Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 653925BDBM653925(US11912682, Compound 23)
Affinity DataIC50: 500nMAssay Description:Compound activity was monitored in a fluorescence polarization (FP) homogeneous assay using 1-[5-({2-[2-(2-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2024
Entry Details
US Patent

TargetProtein cereblon(Human)
Monte Rosa Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 654052BDBM654052(US11912682, Compound 152)
Affinity DataIC50: 500nMAssay Description:Compound activity was monitored in a fluorescence polarization (FP) homogeneous assay using 1-[5-({2-[2-(2-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2024
Entry Details
US Patent

TargetProtein cereblon(Human)
Monte Rosa Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 653969BDBM653969(US11912682, Compound 67)
Affinity DataIC50: 800nMAssay Description:Compound activity was monitored in a fluorescence polarization (FP) homogeneous assay using 1-[5-({2-[2-(2-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2024
Entry Details
US Patent

TargetProtein cereblon(Human)
Monte Rosa Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 653970BDBM653970(US11912682, Compound 68)
Affinity DataIC50: 800nMAssay Description:Compound activity was monitored in a fluorescence polarization (FP) homogeneous assay using 1-[5-({2-[2-(2-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2024
Entry Details
US Patent

TargetProtein cereblon(Human)
Monte Rosa Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 653964BDBM653964(US11912682, Compound 62)
Affinity DataIC50: 800nMAssay Description:Compound activity was monitored in a fluorescence polarization (FP) homogeneous assay using 1-[5-({2-[2-(2-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2024
Entry Details
US Patent

TargetProtein cereblon(Human)
Monte Rosa Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 653966BDBM653966(US11912682, Compound 64)
Affinity DataIC50: 800nMAssay Description:Compound activity was monitored in a fluorescence polarization (FP) homogeneous assay using 1-[5-({2-[2-(2-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2024
Entry Details
US Patent

TargetProtein cereblon(Human)
Monte Rosa Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 653979BDBM653979(US11912682, Compound 77)
Affinity DataIC50: 800nMAssay Description:Compound activity was monitored in a fluorescence polarization (FP) homogeneous assay using 1-[5-({2-[2-(2-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2024
Entry Details
US Patent

TargetProtein cereblon(Human)
Monte Rosa Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 653978BDBM653978(US11912682, Compound 76)
Affinity DataIC50: 800nMAssay Description:Compound activity was monitored in a fluorescence polarization (FP) homogeneous assay using 1-[5-({2-[2-(2-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2024
Entry Details
US Patent

TargetProtein cereblon(Human)
Monte Rosa Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 653974BDBM653974(US11912682, Compound 72)
Affinity DataIC50: 800nMAssay Description:Compound activity was monitored in a fluorescence polarization (FP) homogeneous assay using 1-[5-({2-[2-(2-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2024
Entry Details
US Patent

TargetProtein cereblon(Human)
Monte Rosa Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 653953BDBM653953(US11912682, Compound 51)
Affinity DataIC50: 800nMAssay Description:Compound activity was monitored in a fluorescence polarization (FP) homogeneous assay using 1-[5-({2-[2-(2-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2024
Entry Details
US Patent

Displayed 1 to 50 (of 155 total ) | Next | Last >>
Jump to: